27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Providing a dementia diagnosis is challenging, especially in primary care and considering diverse patient backgrounds. 5 key findings →
Design: systematic-review Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Neuroinflammation drives Alzheimer's disease (AD) pathogenesis. 2 key findings →
Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Clinical and experimental evidence suggest that dopaminergic transmission is impaired in FTD. 2 key findings →
Participants: 128 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) involves a dynamic interaction between neuroinflammation and metabolic dysregulation, where microglia play a central role. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers may aid Alzheimer disease (AD) diagnosis and prognosis. 4 key findings →
Participants: 301 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The characteristics of the cohort revealed significant groupwise differences in age, education, sex, and cognitive diagnosis. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neighborhood disadvantage was associated with worse cognitive performance on memory, executive function, processing speed, and preclinical Alzheimer's tests on both datasets. 5 key findings →
Participants: 524 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The sample (n = 26,728) was equally distributed across gender (55.1% women) and education (50.8% completed HS/GED diploma), and 30% came from under-represented racial/ethnic groups. 5 key findings →
Design: cross-sectional Participants: 26,728 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study included 74,275 weeks of driving data (2015-2024, average follow-up 6.1 years). 5 key findings →
Design: longitudinal study Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A significant ADI × dementia interaction was observed for global atrophy (p = .005) and several other outcomes. 5 key findings →
Design: longitudinal study Participants: 14 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The empirical language composite showed superior and consistent sensitivity (faster decline rate) with all three biomarkers. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 0.81). NfL levels were not significantly associated with GDS-15 in a population of community-dwelling older adults without dementia. 4 key findings →
Design: cross-sectional Participants: 512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.006). Univariable MR analyses indicated that education and participation reduced the risk of AD. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
< 0.001). This study suggests 2 molecular pathways underlying CAA, with a larger effect size for the pathway including SFRP1 and APOE protein and C-terminally truncated Aβ before position 40. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This narrative review examines the utility of gait digital biomarkers in Parkinson's disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multimorbidity-the co-occurrence of two or more chronic health conditions-affects > 86% of people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found a wide range of behavioural changes across FTD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study included 685 patients who underwent MDS-cognitive and 3,630 patients assessed using OASIS. 5 key findings →
Design: cohort study Participants: 685 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
No model terms met the a priori cut-off beyond the base model, including device type, response input source (e.g. mouse, etc.), or session interference. 5 key findings →
Participants: 167 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Higher BAG (pDeepBrainNet = 0.0002; pBrainAgeR = 0.00117) and lower hippocampal volume (p = 0.0015) and cortical thickness (p < 0.0001) were associated with worse clinical status (higher CDR). 2 key findings →
Participants: 2,870 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Superficial white matter (SWM), containing short-range association connections beneath the cortex, has been affected in mild cognitive impairment and AD, with gaps in understanding the disease's early stages. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinical stages showed a progressively increased prevalence of Aβ-positivity and higher entorhinal tau PET pathology from cognitively normal (CN) to SOCD, MCI, and dementia in both tracers. 5 key findings →
Design: longitudinal study Participants: 446 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The AI-powered pipeline achieved robust performance with intraclass correlation coefficients exceeding 0.97 for regional uptake estimation compared with MR-based ground truth. 5 key findings →
Design: longitudinal study Participants: 666 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Female caregivers perceived a greater care burden than male caregivers. 5 key findings →
Participants: 3,067 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →